Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 49
Filter
1.
Clin Dysmorphol ; 2024 Mar 22.
Article in English | MEDLINE | ID: mdl-38856641

ABSTRACT

Camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome (MIM# 208250) is a rare monogenic disorder, characterized by early onset of camptodactyly, progressive coxa vara, bilateral arthropathy and constrictive pericarditis. The syndrome is caused by biallelic loss-of-function variants in PRG4. Deficiency of PRG4 results in progressive worsening of joint deformity with age. Thirteen individuals with CACP syndrome from eight consanguineous Indian families were evaluated. We used exome sequencing to elucidate disease-causing variants in all the probands. These variants were further validated and segregated by Sanger sequencing, confirming the diagnosis of CACP syndrome in them. Seven females and six males aged 2-23 years were studied. Camptodactyly (13/13), coxa vara (11/13), short femoral neck (11/13) and arthritis in large joints (12/13) [wrists (11/13), ankle (11/13), elbow (10/13) and knee (10/13)] were observed commonly. Five novel disease-causing variants (c.3636G>T, c.1935del, c.1134dup, c.1699del and c.962T>A) and two previously reported variants (c.1910_1911del and c.2816_2817del) were identified in homozygous state in PRG4. We describe the phenotype and mutations in one of the large cohorts of patients with CACP syndrome, from India.

2.
Int J Rheum Dis ; 27(6): e15243, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38925615

ABSTRACT

INTRODUCTION: Mixed connective tissue disease (MCTD) is a rare entity in children. There is a paucity of studies on juvenile-onset MCTD (jMCTD) worldwide especially from Southeast Asia. OBJECTIVES: To describe clinical and laboratory features of jMCTD diagnosed at pediatric rheumatology centers across India. METHODS: A predesigned detailed case proforma in an excel format was prepared and was sent to all the Pediatric Rheumatology centers in India. Eleven centers provided the clinical and laboratory data of their jMCTD patients, which was then compiled and analyzed in detail. RESULTS: Thirty-one jMCTD patients from 11 centers were included in the study. Our cohort had 27 females and four male patients over 12 months (August 2021 to July 2022). The median age at presentation was 12 years (range 5-18 years) and the median duration of symptoms was 24 months at diagnosis (range 2-96 months). The common features included arthritis (90%), malar rash (70.9%), and Raynaud's phenomenon (70.9%). At a mean follow-up of 43 months (range 1-168 months), 45% of them were in remission. There were two deaths reported, due to macrophage activation syndrome and sepsis respectively. CONCLUSION: We present the largest multicenter experience on jMCTD from the Indian subcontinent. The study's findings serve as a crucial stepping stone toward unraveling the complexities of jMCTD and improving patient care and management strategies.


Subject(s)
Mixed Connective Tissue Disease , Humans , Child , Male , Female , Mixed Connective Tissue Disease/diagnosis , Mixed Connective Tissue Disease/therapy , Mixed Connective Tissue Disease/epidemiology , India/epidemiology , Adolescent , Child, Preschool , Treatment Outcome , Age of Onset , Immunosuppressive Agents/therapeutic use , Antirheumatic Agents/therapeutic use , Retrospective Studies , Time Factors , Remission Induction
4.
Indian J Pediatr ; 2023 Dec 12.
Article in English | MEDLINE | ID: mdl-38085415

ABSTRACT

Besides genetic susceptibility, infections due to viruses, bacteria and protozoa have been implicated in the development of autoimmune diseases (AD). AD can be triggered in a genetically susceptible individual by infections that disrupt immunological tolerance towards self-antigens. Pathogens can initiate autoimmunity by way of molecular mimicry, bystander activation, epitope spreading or persistent infection with polyclonal activation. This review covers two main topics: (i) the mechanisms by which an infectious agent can trigger or worsen autoimmunity; and (ii) the correlation between specific infectious agents and AD in humans with special emphasis on multisystem inflammatory syndrome in children (MIS-C).

5.
Sci Rep ; 13(1): 19475, 2023 Nov 09.
Article in English | MEDLINE | ID: mdl-37945609

ABSTRACT

The growth in AI is rapidly transforming the structure of economic production. However, very little is known about how within-AI specialization may relate to broad-based economic diversification. This paper provides a data-driven framework to integrate the interconnection between AI-based specialization with goods and services export specialization to help design future comparative advantage based on the inherent capabilities of nations. Using detailed data on private investment in AI and export specialization for more than 80 countries, we propose a systematic framework to help identify the connection from AI to goods and service sector specialization. The results are instructive for nations that aim to harness AI specialization to help guide sources of future competitive advantage. The operational framework could help inform the public and private sectors to uncover connections with nearby areas of specialization.

6.
Indian J Ophthalmol ; 71(5): 1986-1993, 2023 05.
Article in English | MEDLINE | ID: mdl-37203070

ABSTRACT

Purpose: To report the spectrum of posterior segment manifestations and visual outcomes in a large series of patients with systemic lupus erythematosus (SLE). Methods: Retrospective study at a tertiary referral eye center in south India between 2016 and 2022. Results: Charts of 109 patients diagnosed to have SLE were retrieved from our medical database. Only nine cases of SLE (8.25%) had posterior segment involvement. The male: female ratio was 1:8. The mean age was 28 years. Unilaterality was the most common presentation in eight cases (88.89%). Lupus nephritis was the most common systemic presentation in five cases (55.56%). Antiphospholipid antibodies (APLA) positivity was seen in two cases (22.22%). Ocular manifestations included microangiopathy (cotton wool spots) in one case, occlusive retinal vasculitis with cotton wool spots in four cases (five eyes), optic disc edema with combined venous and arterial occlusion (one case), central retinal vein occlusion with cotton wool spots and hemorrhages (one case), macular edema (four cases), posterior scleritis with optic disc edema and exudative retinal detachment in the posterior pole (one case), and tubercular choroidal granuloma (one case). Treatment included systemic steroids, hydroxychloroquine sulfate (HCQS), and immunosuppression in all cases, blood thinners in two cases, and laser photocoagulation in four cases. HCQS-related retinal toxicity was not seen in any of the 109 cases. Ocular manifestation was the initial presentation of SLE in one case. Visual outcome was poor in three cases. Conclusion: Presence of posterior segment findings in cases with SLE may suggest a severe systemic disease. Early detection and aggressive treatment result in better visual outcomes. Ophthalmologists could play a vital role in guiding systemic therapy.


Subject(s)
Eye Diseases , Lupus Erythematosus, Systemic , Papilledema , Retinal Vein Occlusion , Humans , Male , Female , Adult , Retrospective Studies , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/therapy
7.
Neurol India ; 70(1): 300-303, 2022.
Article in English | MEDLINE | ID: mdl-35263900

ABSTRACT

Background: Juvenile dermatomyositis (JDM) is one of the commonest forms of inflammatory myositis in childhood. Objective: The objective study was to study the clinical characteristics and course of JDM patients. Material and Methods: Retrospective analysis of the charts of 25 JDM patients admitted to two hospitals in Bangalore from March 2011 to July 2017. Results: The mean age at onset of disease was 7.74 ± 3.74 years. The male to female ratio was 1.5:1. All patients had skin rashes typical of JDM and 24/25 had demonstrable muscle weakness. Six patients were either lost to follow-up or died. Of the remaining 19 patients, 11 (57.9%) had a monocyclic course, 5 (26.3%) patients had a chronic continuous course, and 3 (15.8%) patients had a polycyclic course. Conclusions: JDM though rare should always be considered in the differential diagnosis in any child with skin rash and muscle pains and weakness. When diagnosed early and treated appropriately, sustained remission without medications is possible in a good proportion of patients.


Subject(s)
Dermatomyositis , Myositis , Child , Child, Preschool , Dermatomyositis/complications , Dermatomyositis/diagnosis , Female , Humans , India , Male , Muscle Weakness/etiology , Retrospective Studies
8.
Neurochem Int ; 149: 105146, 2021 10.
Article in English | MEDLINE | ID: mdl-34343653

ABSTRACT

Embolic stroke results in a necrotic core of cells destined to die, but also a peri-ischemic, watershed penumbral region of potentially salvageable brain tissue. Approaches to effectively differentiate between the ischemic and peri-ischemic zones is critical for novel therapeutic discovery to improve outcomes in survivors of stroke. MicroRNAs are a class of small non-coding RNAs regulating gene translation that have region- and cell-specific expression and responses to ischemia. We have previously reported that global inhibition of cerebral microRNA-200c after experimental stroke in mice is protective, however delineating the post-stroke sub-regional and cell-type specific patterns of post-stroke miR-200c expression are necessary to minimize off-target effects and advance translational application. Here, we detail a novel protocol to visualize regional miR-200c expression after experimental stroke, complexed with visualization of regional ischemia and markers of oxidative stress in an experimental stroke model in mice. In the present study we demonstrate that the fluorescent hypoxia indicator pimonidazole hydrochloride, the reactive-oxygen-species marker 8-hydroxy-deoxyguanosine, neuronal marker MAP2 and NeuN, and the reactive astrocyte marker GFAP can be effectively complexed to determine regional differences in ischemic injury as early as 30 min post-reperfusion after experimental stroke, and can be effectively used to distinguish ischemic core from surrounding penumbral and unaffected regions for targeted therapy. This multi-dimensional post-stroke immunofluorescent imaging protocol enables a greater degree of sub-regional mechanistic investigation, with the ultimate goal of developing more effective post-stroke pharmaceutical therapy.


Subject(s)
Ischemic Attack, Transient/metabolism , Ischemic Stroke/metabolism , MicroRNAs/biosynthesis , Reactive Oxygen Species/metabolism , Animals , Cell Hypoxia/physiology , Gene Expression , Ischemic Attack, Transient/genetics , Ischemic Stroke/genetics , Male , Mice , Mice, Inbred C57BL , MicroRNAs/genetics
9.
Bioresour Technol ; 330: 125012, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33773265

ABSTRACT

Sugarcane is an important cash crop used for producing sweeteners and also some bioproducts (alcohol and bioenergy). The current study assesses life cycle energy, carbon and water footprint of sugarcane based sugar, ethanol and electricity in India. A farm to factory gate attributional life cycle assessment (LCA) is conducted to assess the energy and carbon footprints whereas the Food and Agriculture Organization's (FAO) CropWat model is used to estimate the water footprint (green, blue and grey). For the base case, electricity has the highest energy return on investment (EROI), lowest carbon and water footprints among the bioproducts. The choice of allocation method (economic, mass, and energy) impacts the energy and environmental outcomes of the bioproducts. The comparison among four different sugarcane seasons shows that bioproducts available from Adsali sugarcane have the highest EROI, lowest carbon and water footprints. The findings could lead to improved sustainability of sugarcane bioproducts in India.


Subject(s)
Carbon Footprint , Saccharum , Animals , Carbon , Electricity , Ethanol , India , Life Cycle Stages , Sugars , Water
11.
Ocul Immunol Inflamm ; 29(2): 250-256, 2021 Feb 17.
Article in English | MEDLINE | ID: mdl-32293936

ABSTRACT

Purpose: To report the clinical profile of genetically proven Blau syndrome in seven cases from a single center in South India.Materials & Methods: Retrospective case seriesResults: There were four females and three males. All cases had a history of skin and joint involvement of varying severity. Flexion contractures of the proximal interphalangeal joints were seen in all cases except Case 2. Ocular involvement was bilateral and included keratoconjunctivitis sicca (six cases), granulomatous panuveitis (three cases), granulomatous anterior uveitis (three cases), conjunctival granulomas (three cases), subepithelial corneal opacities (one case), and subretinal granuloma (one case). Other ocular findings included band-shaped keratopathy (five cases) and cataract (three cases). All cases received oral steroids and methotrexate with an addition of mycophenolate mofetil in one case. Visual prognosis was good in all cases.Conclusions: Blau syndrome is underreported in India. This is the largest case series of genetically proven Blau syndrome from South India and highlights the clinical profile of Blau syndrome seen in India.


Subject(s)
Arthritis/genetics , Conjunctiva/diagnostic imaging , Cornea/diagnostic imaging , Keratoconjunctivitis Sicca/etiology , Mutation , Nod2 Signaling Adaptor Protein/genetics , Sarcoidosis/genetics , Synovitis/genetics , Uveitis/genetics , Visual Acuity , Arthritis/complications , Arthritis/diagnosis , Child , Child, Preschool , DNA/genetics , DNA Mutational Analysis , Female , Humans , India , Keratoconjunctivitis Sicca/diagnosis , Keratoconjunctivitis Sicca/physiopathology , Male , Nod2 Signaling Adaptor Protein/metabolism , Retrospective Studies , Sarcoidosis/complications , Sarcoidosis/diagnosis , Slit Lamp Microscopy , Synovitis/complications , Synovitis/diagnosis , Uveitis/complications , Uveitis/diagnosis
12.
J Rheumatol ; 48(6): 898-906, 2021 06.
Article in English | MEDLINE | ID: mdl-33191283

ABSTRACT

OBJECTIVE: To develop and test shortened versions of the Manual Muscle Test-8 (MMT-8) in juvenile dermatomyositis (JDM). METHODS: Construction of reduced tools was based on a retrospective analysis of individual scores of MMT-8 muscle groups in 3 multinational datasets. The 4 and 6 most frequently impaired muscle groups were included in MMT-4 and MMT-6, respectively. Metrologic properties of reduced tools were assessed by evaluating construct validity, internal consistency, discriminant ability, and responsiveness to change. RESULTS: Neck flexors, hip extensors, hip abductors, and shoulder abductors were included in MMT-4, whereas MMT-6 also included elbow flexors and hip flexors. Both shortened tools revealed strong correlations with MMT-8 and other muscle strength measures. Correlations with other JDM outcome measures were in line with predictions. Internal consistency was good (0.88-0.96) for both MMT-4 and MMT-6. Both reduced tools showed strong ability to discriminate between disease activity states, assessed by the caring physician or a parent (P < 0.001), and between patients whose parents were satisfied or not satisfied with illness course (P < 0.001). Responsiveness to change (assessed by both standardized response mean and relative efficiency) of MMT-4 and, to a lesser degree, MMT-6, was slightly superior to that of MMT-8. CONCLUSION: Overall, the metrologic performance of MMT-4 and MMT-6 was comparable to that of the other established muscle strength tools, which indicates that they may be suitable for use in clinical practice and research, including clinical trials. The measurement properties of these tools should be further tested in other patient populations and evaluated prospectively.


Subject(s)
Dermatomyositis , Dermatomyositis/diagnosis , Humans , Muscle Strength , Muscle, Skeletal , Muscles , Outcome Assessment, Health Care , Retrospective Studies
13.
J Dairy Sci ; 103(12): 11079-11085, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33222848

ABSTRACT

The main objective of this work was to develop an analytical method that can be used in a dairy manufacturing facility for the quantitation of phospholipids in dairy products. Total lipids from a dairy matrix were obtained first by Folch extraction. The total lipid extract was then applied to a silica gel-based solid-phase extraction column, and triglycerides and other nonpolar lipids were separated from the phospholipids and sphingolipids. Quantitation was performed by hydrophilic interaction HPLC coupled to evaporative light-scattering detection using a quaternary separation method. The method was validated using a commercial whey protein phospholipid concentrate and was used to analyze phospholipid and sphingolipid composition in buttermilk, whey protein concentrate, whey protein phospholipid concentrate, and several other dairy ingredients. This method was sensitive and reproducible and can be used in the dairy industry as a research tool to develop new value-added dairy phospholipid products, then later as a standard protocol for quality assurance analysis of current and future products.


Subject(s)
Chromatography, High Pressure Liquid/methods , Dairy Products/analysis , Phospholipids/analysis , Whey Proteins/analysis , Animals , Hydrophobic and Hydrophilic Interactions , Light , Scattering, Radiation , Solid Phase Extraction/methods , Sphingolipids/analysis
15.
Indian Pediatr ; 57(11): 1040-1048, 2020 11 15.
Article in English | MEDLINE | ID: mdl-32471961

ABSTRACT

OBJECTIVE: To formulate practice guidelines on diagnosis and management of Kawasaki disease (KD) for Indian children. JUSTIFICATION: KD is a systemic vasculitis that predominantly affects infants and children less than 5 years of age. Coronary artery abnormalities (CAA) develop in around 15-25% of untreated children with KD. Coronary artery involvement can lead to long-term cardiovascular implications such as development of premature coronary artery disease. Diagnosis of KD is essentially clinical based on recognition of a constellation of characteristic symptoms and signs. Timely diagnosis and initiation of intravenous immunoglobulin (IVIG) therapy is known to produce five-fold reduction in the incidence of CAA. As there is no confirmatory laboratory test for KD, the diagnosis may be missed if one is not familiar with the nuances of clinical diagnosis. PROCESS: A committee was formed under the auspices of Indian Academy of Pediatrics in early 2018 for preparing guidelines on KD in Indian children. A meeting of the consultative committee was held in Mumbai, and a draft protocol was devised. All members scrutinized the recent publications on the subject and an attempt was made to arrive at a broad consensus. Published guidelines on the subject were also reviewed. RECOMMENDATIONS: The diagnosis is clinical and is aided by laboratory and 2D echocardiography. First line of therapy is IVIG, and should be started expeditiously once the diagnosis is made.


Subject(s)
Mucocutaneous Lymph Node Syndrome , Pediatrics , Child , Echocardiography , Humans , Immunoglobulins, Intravenous/therapeutic use , Infant , Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/drug therapy , Mucocutaneous Lymph Node Syndrome/epidemiology , Retrospective Studies
16.
Indian J Ophthalmol ; 67(6): 975-977, 2019 06.
Article in English | MEDLINE | ID: mdl-31124539

ABSTRACT

A 13-year-old boy with a 4-year history of idiopathic pediatric uveitis and recurrent uveitic macular edema had failed conventional immunomodulatory therapy and presented to us with a vision of 6/24 [right eye (OD)] and 6/9 [left eye (OS)]. Fluorescein angiography showed diffuse vascular leakage along with cystoid macular edema (CME). Intravenous tocilizumab (10 mg/kg body) was given as 14 injections over 12 months. Repeat fluorescein angiography every 3 months showed a dramatic improvement in the vascular leakage and resolution of CME. At 13 months OF follow-up, vision had improved to 6/9p (OD) and 6/6(OS) with no recurrence of inflammation or CME.


Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Macula Lutea/pathology , Macular Edema/drug therapy , Uveitis/drug therapy , Adolescent , Fluorescein Angiography , Follow-Up Studies , Fundus Oculi , Humans , Injections, Intravenous , Macular Edema/complications , Macular Edema/diagnosis , Male , Tomography, Optical Coherence , Uveitis/complications , Uveitis/diagnosis , Visual Acuity
17.
Neuromolecular Med ; 21(2): 170-181, 2019 06.
Article in English | MEDLINE | ID: mdl-30900118

ABSTRACT

Mild traumatic brain injury (mTBI) can result in permanent impairment in memory and learning and may be a precursor to other neurological sequelae. Clinical treatments to ameliorate the effects of mTBI are lacking. Inhibition of microRNA-181a (miR-181a) is protective in several models of cerebral injury, but its role in mTBI has not been investigated. In the present study, miR-181a-5p antagomir was injected intracerebroventricularly 24 h prior to closed-skull cortical impact in young adult male mice. Paw withdrawal, open field, zero maze, Y maze, object location and novel object recognition tests were performed to assess neurocognitive dysfunction. Brains were assessed immunohistologically for the neuronal marker NeuN, the perineuronal net marker wisteria floribunda lectin (WFA), cFos, and the interneuron marker parvalbumin. Protein quantification was performed with immunoblots for synaptophysin and postsynaptic density 95 (PSD95). Fluorescent in situ hybridization was utilized to localize hippocampal miR-181a expression. MiR-181a antagomir treatment reduced neuronal miR-181a expression after mTBI, restored deficits in novel object recognition and increased hippocampal parvalbumin expression in the dentate gyrus. These changes were associated with decreased dentate gyrus hyperactivity indicated by a relative reduction in PSD95 and cFos expression. These results suggest that miR-181a inhibition may be a therapeutic approach to reduce hippocampal excitotoxicity and prevent cognitive dysfunction following mTBI.


Subject(s)
Antagomirs/therapeutic use , Brain Injuries, Traumatic/therapy , Exploratory Behavior/drug effects , Head Injuries, Closed/therapy , MicroRNAs/antagonists & inhibitors , Parvalbumins/biosynthesis , Recognition, Psychology/drug effects , Animals , Antagomirs/administration & dosage , Antagomirs/pharmacology , Brain Injuries, Traumatic/genetics , Brain Injuries, Traumatic/metabolism , Cerebral Cortex/chemistry , Cerebral Cortex/injuries , Cerebral Cortex/pathology , Computer Simulation , Head Injuries, Closed/genetics , Head Injuries, Closed/metabolism , Hippocampus/chemistry , Hippocampus/injuries , Hippocampus/pathology , Hyperalgesia/etiology , Hyperalgesia/genetics , Hyperalgesia/prevention & control , Male , Maze Learning , Memory Disorders/etiology , Memory Disorders/genetics , Memory Disorders/prevention & control , Mice , Mice, Inbred C57BL , MicroRNAs/biosynthesis , MicroRNAs/genetics , Open Field Test , Parvalbumins/genetics , Premedication , Random Allocation , Single-Blind Method , Synapses/chemistry
18.
Rheumatology (Oxford) ; 58(7): 1196-1205, 2019 07 01.
Article in English | MEDLINE | ID: mdl-30690571

ABSTRACT

OBJECTIVE: To develop a composite DAS for JDM and provide preliminary evidence of its validity. METHODS: The Juvenile DermatoMyositis Activity Index (JDMAI) is composed of four items: physician's global assessment of overall disease activity; parent's/child's global assessment of child's wellbeing; measurement of muscle strength; and assessment of skin disease activity. The score of the JDMAI is the arithmetic sum of the scores of each individual component. Six versions of the JDMAI were tested, which differed in the tools used to assess the third and fourth items. Validation procedures were conducted using three large multinational patient samples including a total of 627 patients. RESULTS: The JDMAI was found to possess face and content validity, good construct validity, satisfactory internal consistency (Cronbach's alpha = 0.58-0.89), fair responsiveness to clinically important change (standardized response mean = 0.82-3.12 among patients improved) and strong capacity to discriminate patients judged as being in the state of inactive disease or low, moderate or high disease activity by the physician (P < 0.001) or whose parents were satisfied or not satisfied with the course of their child's illness (P < 0.001). Overall, the six versions of the JDMAI showed similar metrological performances in validation analyses. CONCLUSION: The JDMAI was found to possess good measurement properties in a large population of patients with a wide range of disease activity, and is, therefore, suitable for use in both clinical and research settings. The final version of the JDMAI will be selected after its prospective validation.


Subject(s)
Dermatomyositis/diagnosis , Severity of Illness Index , Attitude to Health , Child , Child, Preschool , Dermatomyositis/physiopathology , Dermatomyositis/therapy , Factor Analysis, Statistical , Female , Humans , Male , Muscle Strength , Outcome Assessment, Health Care/methods , Parents/psychology , Quality of Life , Reproducibility of Results
19.
Prog Neurobiol ; 176: 73-85, 2019 05.
Article in English | MEDLINE | ID: mdl-30121237

ABSTRACT

Cerebral ischemia remains a major cause of death and disability worldwide, yet therapeutic options remain limited. Differences in sex and age play an important role in the final outcome in response to cerebral ischemia in both experimental and clinical studies: males have a higher risk and worse outcome than females at younger ages and this trend reverses in older ages. Although the molecular mechanisms underlying sex dimorphism are complex and are still not well understood, studies suggest steroid hormones, sex chromosomes, differential cell death and immune pathways, and sex-specific microRNAs may contribute to the outcome following cerebral ischemia. This review focuses on differential effects between males and females on cell death and immunological pathways in response to cerebral ischemia, the central role of innate sex differences in steroid hormone signaling, and upstreamregulation of sexually dimorphic gene expression by microRNAs.


Subject(s)
Brain Ischemia , MicroRNAs , Sex Characteristics , Adaptive Immunity/physiology , Animals , Female , Humans , Immunity, Innate/physiology , Male , Stroke/genetics , Stroke/immunology , Stroke/physiopathology , Transcriptome
20.
Indian J Orthop ; 52(6): 672-677, 2018.
Article in English | MEDLINE | ID: mdl-30532310

ABSTRACT

BACKGROUND: Chronic recurrent multifocal osteomyelitis (CRMO) is a rare auto-inflammatory disease of the bone. It tends to be multifocal and usually the symptoms tend to run for months and years before diagnosis is usually made. The objective of our study was to understand the clinical presentation and short-term response to treatment of CRMO patients. MATERIALS AND METHODS: A retrospective analysis of patients diagnosed with CRMO between 2011 and 2016 was done. Case records of these were retrospectively reviewed for clinical features, investigations and treatment received. RESULTS: Six patients were diagnosed with CRMO. The median age of onset and time to diagnosis from onset of symptoms was 8 and 3.5 years respectively. Lower limb bones were the most commonly involved. CONCLUSIONS: There is significant delay in diagnosis of CRMO and this could be because of a lack of awareness of this condition amongst clinicians. Our case series with only male affection is rather unique as compared to other case series reported in medical literature which tend to have more female predilection. Pain with or without swelling was the most common symptom. Most of patients responded to combination therapy.

SELECTION OF CITATIONS
SEARCH DETAIL
...